|View printer-friendly version|
|Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra® (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis|
New site – www.AmpyraJourneys.com – is first to focus exclusively on walking problems for people living with MS, with patient profiles, medical information, and opportunities for visitors to post messages of inspiration to help others.
The Ampyra Journeys website features true stories of people living with
MS who have experienced walking problems and who took action to get
treatment. Their stories explore the impact that walking problems can
have for people living with MS, and how treatment that leads to
improvements in walking can help people to regain the ability to perform
many daily tasks. Prominent MS patient advocate, motivational speaker
“I have met so many people living with MS who did not seek help when they started to experience walking problems. The important news is that treatment is available, and so I am very excited to be involved with Ampyra Journeys. This new website is a vital resource that can help anyone living with MS to learn about, and to do something about, MS-related walking problems,” said Ms. Salerno Kent.
Walking problems are a significant concern for people living with MS.
According to a 2011
Visitors to www.AmpyraJourneys.com can also download “Let’s Talk About Walking and MS,” a guide with tips on how to talk about walking problems with a healthcare provider.
“Acorda Therapeutics developed Ampyra to help patients with walking
problems, one of the most challenging and common symptoms of MS. Now we
are very pleased to present Ampyra Journeys, to help more people get the
support they need to get treatment. It's our hope that this site will
educate and inspire people to seek help for their MS-related walking
Important Safety Information
AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.
AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrClless-than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.
AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.
Urinary tract infections were reported more frequently as adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to placebo.
The most common adverse events (incidence greater-than or equal to 2% and at a rate greater than the placebo rate) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.
For full U.S. Prescribing Information and Medication Guide for AMPYRA, please visit: www.AMPYRA.com
About AMPYRA® (dalfampridine)
AMPYRA is a potassium channel blocker approved as a treatment to improve
walking in patients with multiple sclerosis (MS). This was demonstrated
by an increase in walking speed. AMPYRA, which was previously referred
to as Fampridine-SR, is an extended release tablet formulation of
dalfampridine (4-aminopyridine, 4-AP), and is known as prolonged-,
modified, or sustained-release fampridine (FAMPYRA®) in some
In laboratory studies, dalfampridine extended release tablets has been
found to improve impulse conduction in nerve fibers in which the
insulating layer, called myelin, has been damaged. AMPYRA is being
developed and commercialized in the U.S. by
AMPYRA is available by prescription in
Acorda markets AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in
The Company also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride tablets, an
authorized generic version of ZANAFLEX CAPSULES distributed by
Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.